As part of the multiple myeloma research community, we at Novartis are constantly aiming to identify the next big innovation. While there still isn’t a cure for multiple myeloma, as active partners with this community, we are encouraged by how far treatment has evolved and how rapidly it has done so in the past decade.
Through the 1970s, treatment advances for multiple myeloma were limited and the treatment landscape remained largely stagnant1. Thankfully, that changed in the 2000s with an influx of new research and treatment options. Adding these treatments and their mechanisms of action to the treatment arsenal, are changing the way patients and physicians look at multiple myeloma management.
7 Story MM NVSOnc.com Story Hand With Mobile.png
While it’s been an exciting few years in multiple myeloma treatment research, the clinical application is not often a direct path. Universities, medical centers and other organizations around the world, including Novartis, are conducting crucial investigations into multiple myeloma. Each year, our physicians and scientists learn more about what causes multiple myeloma and try to shed more light upon how to improve treatment. As the best and the brightest come together for the American Society of Hematology Annual Meeting (ASH) this year, we look forward to making even more progress for those living with this difficult-to-treat disease.
San Miguel, J F et al. Multiple myeloma: treatment evolution. Hematology. 2012 Apr;17 Suppl 1:S3-6.